Human bactericidal/permeabilityincreasingprotein,BPI ELISA Kit

Code CSB-E09175h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
bactericidal/permeability-increasing protein
Alternative Names
Bactericidal permeability-increasing protein ELISA Kit; Bactericidal/permeability increasing protein ELISA Kit; BPI ELISA Kit; BPI fold containing family D; member 1 ELISA Kit; BPI_HUMAN ELISA Kit; BPIFD1 ELISA Kit; CAP 57 ELISA Kit; CAP57 ELISA Kit; rBPI ELISA Kit; Recombinant BPI holoprotein; rBPI ELISA Kit
Abbreviation
BPI
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, cell culture supernates
Detection Range
1.25 ng/mL-80 ng/mL
Sensitivity
0.31 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human BPI in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 93
Range % 89-97
1:2 Average % 102
Range % 98-106
1:4 Average % 90
Range % 85-94
1:8 Average % 98
Range % 94-102
Recovery
The recovery of human BPI spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 89 84-93
EDTA plasma (n=4) 92 88-96
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected
80 2.695 2.732 2.714 2.618
40 2.285 2.154 2.220 2.124
20 1.431 1.366 1.399 1.303
10 0.827 0.881 0.854 0.758
5 0.412 0.429 0.421 0.325
2.5 0.258 0.247 0.253 0.157
1.25 0.169 0.175 0.172 0.076
0 0.094 0.098 0.096  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The human bactericidal/permeability-increasing protein (BPI) ELISA Kit is used to quantitatively measure human BPI concentrations in serum, plasma, or cell culture supernates. It performs well in important characteristics, including sensitivity and specificity. This assay is based on the sandwich ELISA mechanism and enzyme-substrate chromogenic reaction. The solution color develops proportionally to the amount of BPI in the sample. And the intensity of the color can be measured at 450 nm via a microplate reader.

BPI, a neutrophil-derived protein, is the natural antagonist of LBP since the interaction of BPI with its ligand LPS is strong enough to prohibit the LPS-dependent stimulation of immune cells. In the context of Gram-negative infection, BPI neutralizes the endotoxic activity of lipopolysaccharides, and thus inhibits hyperactivation. BPI functions as an immune-enhancing pattern recognition molecule in Gram-positive infections. In addition to acting as an LPS-neutralizing protein, BPI also has other functions such as inhibition of endothelial cell growth and dendritic cell maturation or being an anti-angiogenic, chemoattractant, or opsonization agent.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa.
Gene References into Functions
  1. BPI G645A polymorphism was associated with a decreased risk of ulcerative colitis; the BPI G645A polymorphism was not associated with the risk of crohn's disease. PMID: 28035462
  2. Bactericidal permeability increasing protein Lys216Glu polymorphism is associated with both Crohn's disease and ulcerative colitis. PMID: 26228368
  3. MPO and BPI in CD4(+)T-lymphocytes, and PDHA1 and MRPL42 in CD8(+) T-lymphocytes might be used as specific biomarkers of severe asthma progression. PMID: 26107902
  4. This review article focuses on the structural and functional properties of BPI with respect to its antimicrobial contribution to host defense during GNB infections and endotoxin-induced inflammation. PMID: 17678885
  5. Diminished PRRs, IFN-signature, and BPI gene expression raises the possibility that impairments in these pathways contribute to the susceptibility of LBW term infants to infection. PMID: 23626859
  6. Lung function and IgA-BPI-ANCA, but not Leeds criteria, were significantly associated with adverse outcome. PMID: 23346184
  7. BPI mutation (PstI in intron 5) and a decreased plasma BPI level were significant risk factors in susceptibility to COPD...BPI genetic mutation and impaired BPI production or release may result in airflow obstruction in smokers. PMID: 22409502
  8. The bactericidal/permeability-increasing protein in the innate defence of the lower airways PMID: 21787345
  9. there is a correlation between the presence of BPI-ANCA, the properties of the colonizing bacteria and the clinical conditions of the host in cystic fibrosis PMID: 21463973
  10. SNP Lys216Glu is associated with Crohn's disease and ulcerative colities PMID: 21272798
  11. Restriction enzyme digestion and DNA sequence analysis revealed that the sequence encoding signal peptide and bioactive N-terminal fragment of BPI had six nucleotide substitutions, compared with that of the established human BPI sequence PMID: 17488601
  12. BPI is the main target antigen for ANCA in tuberculosis and BPI-ANCA increase after treatment PMID: 20412700
  13. Circulating BPI could constitute a biomarker of lipid metabolism in subjects with normal glucose tolerance and could help to identify those subjects with preserved endothelial function. PMID: 20174761
  14. Investigated if serum and salivary anti-BPI autoantibodies appear in the course of acute pneumonia. Presence of anti-BPI IgG on admission didn't correlate with inflammatory markers. Salivary anti-BPI IgA didn't appear during the course of acute pneumonia. PMID: 19702878
  15. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia PMID: 11891303
  16. increased levels in fetal disease, premature rupture of membranes, and preterm labor PMID: 12710851
  17. Constitutive expression of BPI, which increases upon interleukin 4 stimulation, by human dermal fibroblast was demonstrated, suggesting an important role of BPI in gram-negative bacterial clearance and a dampened response to endotoxin in the skin PMID: 12738651
  18. BPI and cathepsin G are the major antigenic targets of ANCA seen in patients with systemic sclerosis PMID: 12784398
  19. BPI and HNP are accumulated in the synovial cavity of patients with rheumatoid arthritis PMID: 12913926
  20. In conclusion, we provide evidence for AML-1, PU.1, and Sp3 cooperatively and directly mediating BPI-expression during myeloid differentiation. PMID: 14623259
  21. BPI could exist in the inner root sheath cells of human and rat hair follicles, and might play a role as a barrier against anaerobic bacteria PMID: 15009116
  22. The BPI stored in human neutrophil granulocytes, is cytotoxic against Gram-negative bacteria. PMID: 15590754
  23. The bactericidal/permeability increasing protein (BPI) is involved in the elimination of gram-negative bacteria. A functionally relevant single nucleotide polymorphism of the BPI gene causes an amino acid exchange (Glu216Lys). PMID: 15758620
  24. Studies of BPI promoter expression in intestinal epithelial cells identified regulatory regions of the BPI promoter and revealed a prominent role for CCAAT/enhancer binding protein and especially Sp1/Sp3 in the basal regulation of BPI. PMID: 16282362
  25. findings suggest that BPI is associated with metabolic pathways PMID: 16380496
  26. BPI that is functionally active against mucoid P. aeruginosa strains is expressed in the airways of Cystic Fibrosis patients but may be hampered by autoantibodies, resulting in chronic infection. PMID: 16861658
  27. The present study does not give evidence for the contribution of the BPI gene to the genetic background of chronic periodontal disease. PMID: 16893388
  28. BPI has unusual dual properties of promoting retinal pericytes and retinal pigment epithelial cell growth while suppressing VEGF-induced retinal epithelial cell growth and vascular permeability PMID: 17012258
  29. Reduces expression of type I inetrferon by antagonizing lipopolysaccharide-binding protein. PMID: 17239348
  30. the requirement for C/EBP epsilon in mediating BPI gene expression in myeloid cells in vitro and in vivo. PMID: 17483073
  31. a novel role of BPI in the interaction of bacterial outer membrane vesicles with dendritic cells that may help link innate immune recognition of endotoxin to Ag delivery and presentation. PMID: 17675509
  32. evaluated the role of genetic polymorphisms of the bactericidal permeability increasing protein (BPI) in pediatric patients with sepsis PMID: 17898994

Show More

Hide All

Subcellular Location
Secreted. Cytoplasmic granule membrane.
Protein Families
BPI/LBP/Plunc superfamily, BPI/LBP family
Tissue Specificity
Restricted to cells of the myeloid series.
Database Links

HGNC: 1095

OMIM: 109195

KEGG: hsa:671

STRING: 9606.ENSP00000262865

UniGene: Hs.529019

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1